Focused On-demand Library for Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q16134

UPID:

ETFD_HUMAN

Alternative names:

Electron-transferring-flavoprotein dehydrogenase

Alternative UPACC:

Q16134; B4E3R9; J3KND9; Q7Z347

Background:

Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial, also known as Electron-transferring-flavoprotein dehydrogenase, plays a pivotal role in the mitochondrial respiratory chain. It accepts electrons from the electron transfer flavoprotein and reduces ubiquinone, facilitating the transfer of electrons from various substrates to the mitochondrial electron transport chain.

Therapeutic significance:

The protein is directly linked to Glutaric aciduria 2C, a metabolic disorder affecting fatty acid, amino acid, and choline metabolism. This association highlights its critical role in metabolic pathways and underscores the potential for targeted therapeutic strategies to address the underlying genetic variants causing this disorder.